Advertisement

Topics

FDA Grants Orphan Drug Designation to Syros’ Investigational Treatment for Acute Myeloid Leukemia

09:54 EDT 21 Aug 2017 | Speciality Pharma Journal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). SY-1425, an oral first-in-class selective retinoic acid receptor alpha …

Original Article: FDA Grants Orphan Drug Designation to Syros’ Investigational Treatment for Acute Myeloid Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to Syros’ Investigational Treatment for Acute Myeloid Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...